Wednesday, April 12, 2023

The Morning: The abortion battle

And what happens next.

Good morning. We explain the dueling rulings on abortion and what's likely to happen next.

Mifepristone and misoprostol tablets.Desiree Rios/The New York Times

Mail fight

The future of abortion — both the practice itself and the legal fight over it — will increasingly revolve around prescription drugs.

That's been evident for a while, and the dueling legal decisions last week about a commonly used abortion drug made it even clearer. In the end, the Supreme Court may need to resolve the dispute and decide whether the drug can continue to be used.

With help from Times reporters who are covering the story, today's newsletter will explain why medication abortion, as the practice is known, is growing so rapidly and what's likely to happen next.

'Existential crisis'

Medication abortion has become more common over the past decade and now accounts for more than half of legal abortions. Typically in the U.S., the treatment involves a combination of two drugs, mifepristone and misoprostol.

The treatment has become more popular partly because many women prefer it to surgical abortion. They can take the drugs at home rather than at a hospital or doctor's office, and the drugs are both highly effective and safe. Emergency rooms see more people suffering side effects from Tylenol, Christina Jewett, who covers the F.D.A. for The Times, pointed out.

"This drug has been studied and scrutinized heavily for more than 20 years," Christina told me. (This graphical review of the evidence is illuminating.)

Since the Supreme Court overruled Roe v. Wade last year, 13 states have banned nearly all abortions, including medication abortions. But some women in those states have been able to get around the bans with a drug prescription. They can briefly travel to another state to receive the pills or can order them by mail (even illegally from an overseas provider, as some abortion-rights advocates have encouraged).

The rise of medication abortion explains why overall abortion rates have not declined as much post-Roe as some people expected. Nationwide, the number of legal abortions per month was 7 percent lower in the final three months of last year than in the months immediately before the Supreme Court ruling, according to a report issued yesterday by the Society of Family Planning. Because the data does not include illegal abortions, the actual decline was likely smaller, my colleague Margot Sanger-Katz said.

Both abortion supporters and opponents understand how important medication abortion has become. "The fact that pills can be mailed is an existential crisis for the anti-abortion movement," Rachel Rebouché, the dean of Temple University's law school, told The Associated Press. "It's hard to police. It's hard to track. It's difficult to enforce."

The rulings

Conservative judges have become bolder in recent years about trying to strike down laws they do not like, and Friday's ruling against mifepristone was part of the trend. In it, Judge Matthew Kacsmaryk, a Donald Trump appointee in Texas, held that the F.D.A. had erred when it approved the drug in 2000.

Some of Kacsmaryk's reasoning seemed plausible on its face: He noted that the agency used a process intended for serious illnesses and argued that pregnancy was not an illness. Other parts of his ruling seemed at odds with reality: He claimed the drug was unsafe. Either way, it was a radical ruling. No court had previously overridden an F.D.A. approval of any drug.

For that reason, even some conservatives criticized the decision. My colleague Adam Liptak wrote that the legal scholars he interviewed described Kacsmaryk's decision as being of "poor quality" and "breathtaking sweep."

Jonathan Adler, a conservative law professor, and The Wall Street Journal's editorial board also criticized the ruling. More than 400 pharmaceutical executives and investors condemned it as being "without regard for science or evidence" and dangerous to many future drug treatments.

On the same day as Kacsmaryk's decision, Thomas Rice — a federal judge in Washington State appointed by Barack Obama — issued an opposing ruling in a different case. Rice granted a request from the Democratic attorneys general of 17 states and Washington, D.C., that the F.D.A. not limit access to mifepristone in their jurisdictions. Rice's ruling could effectively void Kacsmaryk's ruling in those 18 states.

Kacsmaryk placed a one-week delay on the implementation of his decision, to give an appeals court, based in New Orleans, time to review it. The outcome of the appeal may depend on whether the three judges randomly assigned to it happen to be conservative or liberal, but the New Orleans court isn't likely to have the final word. The Supreme Court is.

What's next

Many legal experts say they aren't sure to what to expect. If the appeals court overturns Kacsmaryk's decision, the case could simply end, at least for now. Or the Supreme Court could agree to hear the case and rule that the status quo remains in effect until it rules. In that situation, mifepristone would still be widely available in much of the country but not in the 13 states that virtually ban abortion.

If Kacsmaryk's ruling stands, the F.D.A. and the rest of the Biden administration would have to decide whether they wanted to defy it, using Rice's ruling as justification. Alternately, doctors could decide to offer medication abortion using only misoprostol, as is common in Europe. The misoprostol-only approach is also safe and effective, although side effects, such as painful cramps, can be worse. (Here's an explainer from Pam Belluck.)

Abortion opponents understandably celebrated when the Supreme Court overruled Roe. But even in the new legal landscape, preventing abortion is more difficult than it was in 1973, when the court issued the Roe ruling. The U.S. courts have since made abortion less accessible, but scientific developments — namely the rise of abortion drugs — have pushed in the other direction.

For more

ADVERTISEMENT

Ad

THE LATEST NEWS

Politics
The new rules would be the nation's most ambitious climate regulations to date.Maddie McGarvey for The New York Times
Pentagon Documents Leak
  • The documents appeared on a small social media community devoted to wow_mao, a YouTube figure who said he was an "internet micro-celebrity, and I'd like to keep it that way."
  • Opposition lawmakers in South Korea criticized the documents as evidence of U.S. spying. President Yoon Suk Yeol sought to downplay the disclosures.
International
Other Big Stories
Opinions

"The people of Tennessee and the nation witnessed a travesty against democracy last week," writes Justin Pearson, who was expelled from the Tennessee State Assembly by Republican lawmakers.

What happened to America? Times Opinion spoke with people in their 70s and 80s about the state of the country.

The complete Times subscription.

The Morning offers daily highlights from The Times — but for the complete Times experience, subscribe to All Access.

MORNING READS

Lee Tilghman, a former influencer.Amy Lombard for The New York Times

Internet personality: Is there life after influencing?

Spring cleaning: It has its roots in a dirtier time.

Ask Well: Why does my neck look so much older than my face?

Advice from Wirecutter: How to improve the sound of your headphones.

Lives Lived: Kwame Brathwaite's photographs of celebrities and ordinary people catalyzed the "Black is beautiful" movement of the 1960s and beyond. He died at 85.

SPORTS NEWS FROM THE ATHLETIC

Bruins add another: Last night, Boston picked up the final record of a magical year — the most points ever scored by an N.H.L. team in one season.

N.B.A. play-in tournament: The Raptors play the Bulls and the Pelicans host the Thunder tonight. The teams are fighting for the last playoff spot in each conference.

Women's soccer: The Americans edged Ireland, 1-0, in a friendly thanks to Alana Cook's incredible long-range goal.

ADVERTISEMENT

Ad

ARTS AND IDEAS

Back-seat passengers in BMW's i7 sedan.BMW

Rolling supercomputers

Car designs are prompting a new question: How much screen is too much screen?

Screens have become integral to modern vehicles, combining traditional functions like audio displays with optional content like social media feeds. All those services can distract drivers, as can the screens' increasing sizes and clunky interfaces.

"Screens have their right of existence — they do a lot of things better than physical switches," Klaus Busse, Maserati's head of design, told The Times. "It's just been pushed a little too far."

PLAY, WATCH, EAT

What to Cook
Christopher Testani for The New York Times

Pasta with chopped pesto and peas has bright pops of flavor.

Theater

The musical satire "White Girl in Danger" is set in a fictional soap opera world.

Late Night

The hosts joked about the official end of the Covid era.

Now Time to Play

The pangram from yesterday's Spelling Bee was immediacy. Here is today's puzzle.

Here's today's Mini Crossword, and a clue: Burn slightly (four letters).

And here's today's Wordle.

Thanks for spending part of your morning with The Times. See you tomorrow. — David

P.S. The word "catfluencer" appeared for the first time in The Times recently, in an article about cats who film their own stunts.

"The Daily" is about the Trump case.

The Morning Newsletter Logo

Editor: David Leonhardt

Deputy Editor: Amy Fiscus

News Editor: Tom Wright-Piersanti

News Staff: Lauren Jackson, Sean Kawasaki-Culligan, Brent Lewis, German Lopez, Claire Moses, Ian Prasad Philbrick, Ashley Wu

News Assistant: Lauren Hard

Saturday Writer: Melissa Kirsch

Need help? Review our newsletter help page or contact us for assistance.

You received this email because you signed up for the Morning newsletter from The New York Times, or as part of your New York Times account.

To stop receiving The Morning, unsubscribe. To opt out of other promotional emails from The Times, manage your email preferences.

Subscribe to The Times

Connect with us on:

facebooktwitterinstagram

Change Your EmailPrivacy PolicyContact UsCalifornia Notices

LiveIntent LogoAdChoices Logo

The New York Times Company. 620 Eighth Avenue New York, NY 10018

No comments:

Page List

Blog Archive

Search This Blog

#1 Pre-IPO Opportunity For 2024 [Take Action Now!]

"Larger Than Any IPO Valuation in History" ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ...